Semaglutide injection (Ozempic) and oral tablets (Rybelsus) are now both approved to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes.
The researchers say their findings show a ‘structural shift’ in how care is being delivered, but warn that ‘sustained decrease’ in home visits could result in worse health outcomes for older patients.
The problem is especially acute for those with lower health literacy, notes U.S. cardiologist, as experts from both sides of the border call for better education and access to reliable health information.
